Jiangsu Hengrui Medicine has been granted a patent for a method of treating cancer using a combination of an anti-PD-1 antibody and a VEGFR inhibitor, specifically apatinib. The treatment involves administering the drugs orally within a specified dosage range. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jiangsu Hengrui Medicine Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of February 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Combination of anti-pd-1 antibody and vegfr inhibitor for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Jiangsu Hengrui Medicine Co Ltd

A recently granted patent (Publication Number: US11866500B2) discloses a method for treating cancer in patients by administering a combination of an anti-PD-1 antibody and apatinib or its pharmaceutically acceptable salt. The anti-PD-1 antibody specified in the claims includes specific amino acid sequences for the light and heavy chain variable regions. The method involves oral administration of apatinib at doses ranging from 125 mg to 375 mg, targeting various types of cancer such as breast, lung, liver, gastric, intestinal, renal, melanoma, and non-small cell lung cancer.

Furthermore, the patent outlines specific dosages and administration frequencies for the anti-PD-1 antibody and apatinib, emphasizing the importance of prior chemotherapy failure in the subject before initiating treatment. The anti-PD-1 antibody can be a humanized antibody with defined amino acid sequences, and the method provides flexibility in dosing regimens, ranging from 2 mg/kg to 6 mg/kg body weight or from 100 mg to 1000 mg per administration. The combination therapy aims to enhance the treatment efficacy for cancer patients, offering a detailed framework for administering the anti-PD-1 antibody and apatinib to achieve optimal therapeutic outcomes.

To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies